Epilepsy is a potentially devastating brain disorder characterized by a predisposition to spontaneous epileptic seizures, defined as the occurrence of two unprovoked seizures or one unprovoked seizure with a high probability of recurrence or an epileptic syndrome 1 . In the United States, the incidence and prevalence of epilepsy are 48.7/100,000 and 5.7/1,000 inhabitants, respectively, while in South America the prevalence is estimated to be twice as high 2 . Antiepileptic drugs (AEDs) remain the therapeutic pillar for epilepsy, however, even the best clinical treatment is doomed to fail in about 20% to 40% of patients. These cases are considered refractory, a definition that requires patients to have failed two adequate trials of appropriately-chosen AEDs 3 . People with uncontrolled epilepsy are subjected to many dire consequences, such as falls and the resulting lesions, driving restrictions, work limitations, lack of independence, the need of constant supervision, frequent medical consultations, hospital admissions and medically-related expenses. These result in a significant impact on the quality of life, leading to school absenteeism, unemployment (5-6 times higher than the general population), depression (50-70% prevalence in temporal lobe epilepsy) and other psychiatric conditions, such as generalized anxiety disorder and phobic disorder (56%), often leading to social isolation 4 and even suicide.
Although 25% of patients with epilepsy may be candidates for a surgical approach, a significant portion of them may not benefit from this type of intervention. In such cases, a variety of alternative approaches may be considered, including neuromodulation. The latter is a therapeutic modality that uses electrical or magnetic stimulation inducing short-and long-term modifications in the nervous system circuits. Three types of implantable neurostimulation devices have been introduced and approved for the management of refractory epilepsy: vagus nerve stimulation (VNS), deep brain stimulation (DBS), and responsive neurostimulation systems (RNSs) 5, 6 .
VAGUS NERVE STIMULATION
Currently, more than 100,000 VNS devices have been implanted in more than 80,000 patients 7 . In Brazil, from January 2001 to March 2016, 665 VNS devices were implanted (Politec Health, personal communication).
The vagus nerve stimulator has been approved in Europe (1994), USA (1997) and Brazil (2000) as adjunctive treatment for refractory focal epilepsies to help in reducing the frequency and severity of seizures in patients who are not candidates for conventional surgical treatment. In Brazil, VNS therapy is approved by ANVISA (Agência Nacional de Vigilância Sanitária, or the National Health Agency) for use in patients, at any age, who have been diagnosed with refractory, focal or generalized epilepsy for two or more years.
This device chronically and intermittently stimulates preferentially the left cervical vagus nerve, leading to a reduction in seizure frequency and/or intensity. It is commonly estimated that one year following implantation 52.1% of patients show a seizure frequency reduction of at least 50% 8 . That is frequently accompanied by a potential improvement in mood and alertness, as well as verbal skills, memory, and academic and overall professional performance. Interestingly, these relevant effects may be independent of the reduction in seizure frequency, since similar improvements are reported even in patients in whom seizure reduction is not observed 9 . A number of mechanisms of action have been proposed to try and explain the antiepileptic action of VNS. Structures such as the basal ganglia and thalamus are likely to play an important role via the interference in the electrical brain network leading to desynchronization of cortical electrical activity 10 . In support of this hypothesis, studies show that cutaneous stimulation of vagal afferent fibers and other sensory pathways affect EEG synchrony and sleep cycles 11 . The adverse effects are rather low at about 2%, usually occuring during the "on" phase of stimulation, and have a tendency to decrease over time. The most common complications are postoperative hematoma, infection, and vocal cord paralysis 7 . Voice hoarseness, cough and paresthesias can also occur 7 .
DEEP BRAIN STIMULATION
Deep brain stimulation involves the delivery of a current to the brain parenchyma through deeply implanted electrodes, targeting the anterior nucleus of the thalamus, median nucleus of the thalamus, cerebellar nucleus and others. Over the last decade, a series of preclinical and clinical studies have shown that DBS in the anterior nucleus of the thalamus reduces seizure rates and increases the latency for the development of seizures and status epilepticus 12 .
Knowledge of the basic mechanisms of DBS and of the optimal stimulation parameters is limited. It is postulated that DBS either disrupts or inhibits epileptiform activity around the epileptogenic thalamocortical networks
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. This action is mediated by crucial nodes in the epileptogenic network, such as the anterior nucleus of the thalamus (with its wide limbic and cortical connections), regions involved in sustaining, propagating, or triggering epileptic activity and promoting its inhibition. Even less is known about possible side effects of DBS of the anterior nucleus of the thalamus on cognition and emotion. Optimizing therapeutic effects and minimizing side effects require adjustment of DBS parameters according to knowledge of the therapeutic efficacy, as well as the DBS effects on emotion and cognition 14 .
The Sante study showed many interesting results during their long-term follow-up after DBS implantation, like: a reduction of 40% seizure from baseline at one year and 69% at five years; The responder rate (≥ 50% reduction in seizure frequency) at one year was 43%, and 68% at five years; At the five-year follow-up, 16% of subjects had been seizure-free for at least six months; There were no reported unanticipated adverse device effects or symptomatic intracranial hemorrhages; And the Liverpool Seizure Severity Scale and 31-item Quality of Life in Epilepsy scores showed statistically significant improvement over baseline, both at one year and at five years follow-up (p < 0.001) 15 . The most serious potential side effects of DBS for epilepsy are death, infection, hemorrhage, and status epilepticus. These did not materialize in higher than expected numbers in the SANTE study 16 . More so, the figures for significant side effects in DBS for epilepsy treatment do not differ significantly compared to the DBS implantation in parkinsonian patients 17 . In Brazil, DBS therapy is approved by ANVISA for use in patients with epilepsy who have used VNS without significant improvement for at least two years.
RECOMMENDATIONS FOR VNS AND DBS USE
The aim of this paper is to revise general guidelines for VNS therapy previously published in 2013 18 and establish indications for DBS.
Taking into account the available data, the Neuromodulation Committee for the Brazilian League of Epilepsy (Brazilian Chapter of the International League Against Epilepsy) and the Scientific Department of Epilepsy of the Brazilian Academy of Neurology (Brazilian Chapter of the World Federation of Neurology) suggest that VNS and DBS may be considered as an option for patients with refractory epilepsy at any age, including children 19 and adults, following an evaluation by a neurologist, child neurologist or neurophysiologist with experience in epilepsy and in concordance with the case scenarios listed below.
For VNS use, patients should meet the following criteria 1) Failed to achieve seizure freedom following adequate trials (whether in monotherapy or combined regime) of two tolerated and appropriately chosen and used first-generation AEDs (e.g. phenobarbital, phenytoin, carbamazepine, valproic acid) 3 , plus an additional trial with at least one second or third-generation AED (e.g. oxcarbazepine, lamotrigine, topiramate, vigabatrin, clobazam, levetiracetam and lacosamide), meeting the definition of clinically refractory epilepsy and determining the referral to a specialized epilepsy center.
2) A comprehensive evaluation conducted at a tertiary or higher level epilepsy center should exclude the option for resective surgery, including the use of invasive recording if indicated.
3) Refusal to pursue a resective surgery after a full explanation of risks and benefits of the proposed procedure and thorough explanation regarding the VNS option and its own risks and benefits.
Special situations
Although there is no formal indication for VNS therapy in the following special clinical situations, it may be considered in patients presenting with: 1) Idiopathic generalized epilepsy nonresponsive to broad spectrum AEDs, i.e., levetiracetam, valproic acid and lamotrigine;
2) Progressive myoclonic epilepsy; 3) Genetic/metabolic epilepsies; 4) Super-refractory status epilepticus 20 .
For DBS use, patients should meet the following criteria 1) Remain refractory after the use of VNS for two years, with suitable adjustments and without improvement both in seizure frequency and intensity, i.e., less than 50% improvement.
2) This lack of improvement should be confirmed through adequate assessment performed by a trained epileptologist.
3) If indicated, the device must be implanted by a neurosurgeon with proven experience in neurofunctional surgery, at an institution suitable for high complexity procedures, including full access to CT-scan, MRI 1.5 T or higher, neuronavigation and robotic assistant.
RECOMMENDATIONS FOR VNS ADJUSTMENT AND MANAGEMENT
Vagus nerve stimulation parameters must be adjusted individually by the patient's attending physician, taking into account seizure control and adverse effects, almost as if VNS therapy were an add-on drug in the treatment of epilepsy. The VNS generator is usually turned on one to two weeks after implantation. The initial current is typically set to 0.25 mA, followed by increments of 0.25 mA every two weeks. Faster titration may be attempted, if necessary, according to patient's tolerance. Typical current values for a satisfactory response usually lie between 1.5 mA and 2.5 mA -ranging from 0.5 mA to 3.5 mA -and are usually reached between two to four months after implantation 21 .
Once a satisfactory output current has been reached, other stimulation parameters may be changed -particularly the duty cycle, i.e., on-time/off-time -in an attempt to optimize seizure control. These further changes should be done at longer intervals (every two to three months) to allow better appreciation of the response. Thus, duty cycles may be changed, with shorter duration of stimulation, at shorter intervals. Some reports suggest that, although conventional duty cycles are more effective than rapid cycles in the initial treatment, non-responders may experience significant improvement in seizure control when the duty cycle is increased 22 .
Other parameters such as stimulus frequency and pulse duration may be changed in order to favor tolerance. Thus, stimulus frequency -which ranges between 1 Hz and 30 Hz -is usually set at 30 Hz, but may be reduced to 20 Hz, and pulse width -ranging between 130 µsec and 1000 µsec -is usually set at 500 µsec, but may be reduced to 250 µsec, whenever adverse effects are reported 21 . Finally, every visit should include measuring the remaining battery of the generator and testing the integrity of the system, by measuring the impedance of the circuit. This is particularly important in long-term follow-up, since patients tend to reduce the frequency of their visits once the parameters have been established, and often forget that the battery will eventually run out. Most currently used VNS models have batteries that last anywhere between four and 10 years -varying according to the energy spent -i.e., value of the output current, duty cycle and frequency of use of the magnet 23 .
Final remarks
After careful review of the current literature this committee reached the following conclusions: 1) Vagus nerve stimulation and DBS represent valid neuromodulation tools and, in that order, could be included as treatment options for medically refractory epilepsy patients (both children and adults) who are not suitable for or do not wish to have resective surgery.
2) The indication for VNS or DBS implant should be determined by experienced epileptologists (neurologists, child neurologists and neurophysiologists) after refractory epilepsy confirmation and surgical ward off possibility in a tertiary epilepsy center.
3) The surgery for VNS or DBS implantation should be conducted by functional neurosurgeons, with proven experience. 4) Patients must fully acknowledge the risks and benefits of either of the neuromodulation therapies discussed herein and, in particular, the somewhat limited expectations in rendering these patients completely seizure-free.
